Cohen JA - Search Results

1

Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.

Feng J, Offerman E, Lin J, Fisher E, Planchon SM, Sakaie K, Lowe M, Nakamura K, Cohen JA, Ontaneda D. Feng J, et al. Among authors: cohen ja. Mult Scler J Exp Transl Clin. 2019 Jun 14;5(2):2055217319856035. doi: 10.1177/2055217319856035. eCollection 2019 Apr-Jun. Mult Scler J Exp Transl Clin. 2019. PMID: 31236284 Free PMC article.

2

Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications.

Fox RJ, Fisher E, Tkach J, Lee JC, Cohen JA, Rudick RA. Fox RJ, et al. Among authors: cohen ja. Mult Scler. 2005 Apr;11(2):140-5. doi: 10.1191/1352458505ms1142oa. Mult Scler. 2005. PMID: 15794385 Clinical Trial.

3

Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: results from the IMPACT study.

Miller DM, Cohen JA, Kooijmans M, Tsao E, Cutter G, Baier M. Miller DM, et al. Among authors: cohen ja. Mult Scler. 2006 Apr;12(2):180-6. doi: 10.1191/135248506ms1270oa. Mult Scler. 2006. PMID: 16629421 Clinical Trial.

4

Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.

Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators. Cohen JA, et al. Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208877 Clinical Trial.

5

The use of MR imaging as an outcome measure in multiple sclerosis clinical trials.

Bermel RA, Fisher E, Cohen JA. Bermel RA, et al. Among authors: cohen ja. Neuroimaging Clin N Am. 2008 Nov;18(4):687-701, xi. doi: 10.1016/j.nic.2008.06.008. Neuroimaging Clin N Am. 2008. PMID: 19068409 Review.

6

Multiple sclerosis: new insights in pathogenesis and novel therapeutics.

Ontaneda D, Hyland M, Cohen JA. Ontaneda D, et al. Among authors: cohen ja. Annu Rev Med. 2012;63:389-404. doi: 10.1146/annurev-med-042910-135833. Epub 2011 Sep 1. Annu Rev Med. 2012. PMID: 21888515 Review.

7

Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720).

Ontaneda D, Cohen JA. Ontaneda D, et al. Among authors: cohen ja. Expert Rev Clin Pharmacol. 2011 Sep;4(5):567-70. doi: 10.1586/ecp.11.46. Expert Rev Clin Pharmacol. 2011. PMID: 22114884

8

Revisiting the multiple sclerosis functional composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.

Ontaneda D, LaRocca N, Coetzee T, Rudick R; NMSS MSFC Task Force. Ontaneda D, et al. Mult Scler. 2012 Aug;18(8):1074-80. doi: 10.1177/1352458512451512. Epub 2012 Jun 27. Mult Scler. 2012. PMID: 22740488

9

Early tolerability and safety of fingolimod in clinical practice.

Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA. Ontaneda D, et al. Among authors: cohen ja. J Neurol Sci. 2012 Dec 15;323(1-2):167-72. doi: 10.1016/j.jns.2012.09.009. Epub 2012 Oct 3. J Neurol Sci. 2012. PMID: 23040960 Free PMC article.

10

EDSS improvement: recovery of function or noise?

Ontaneda D, Cohen JA. Ontaneda D, et al. Among authors: cohen ja. Mult Scler. 2012 Nov;18(11):1520-1. doi: 10.1177/1352458512441689. Mult Scler. 2012. PMID: 23100522 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

729 results

Search Page

Filters